6533b856fe1ef96bd12b25d3

RESEARCH PRODUCT

P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer

Liang ShenDaniel Virgil Thomas CatenacciMarkus MoehlerHarry H. YoonH.c. ChungY. KangM. Koshiji Rosales

subject

OncologyChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentMargetuximabAnti pd 1CancerHematologymedicine.diseaseGastroesophageal JunctionFirst line therapyOncologyInternal medicinemedicinebusinesshttps://doi.org/10.1016/j.annonc.2021.05.193